First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
Resource
J. Clin. Oncol., 33(15),
Journal
J. Clin. Oncol.
Journal Volume
33
Journal Issue
15
Pages
-
Date Issued
2015
Date
2015
Author(s)
Tan, Daniel Shao-Weng
Seto, Takashi
Leighl, Natasha B.
Riely, Gregory J.
Sequist, Lecia V.
Felip, Enriqueta
Wolf, Juergen
Yang, James Chih-Hsin
Matushansky, Igor
Yu, Xiaolu
Schmitz, Shu-Fang Hsu
Cui, Xiaoming
Kim, Dong-Wan
SDGs